Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10119596 | 0.86 | NPC1 (0.52) | MAPTNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL38750 | 0.86 | NPC1 (0.52) | MAPTNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL38663 | 0.83 | PPARA (0.51) | MAPTNPC1RAB9ALMNAMAPK1 | |
| SCHEMBL43048 | 0.83 | PPARA (0.51) | MAPTNPC1RAB9ALMNAMAPK1 | |
| SCHEMBL38787 | 0.83 | MAPT (0.55) | MAPTNPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL14699620 | 0.83 | MAPT (0.55) | MAPTNPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL12966546 | 0.82 | PPARA (0.57) | MAPTNPC1RAB9ALMNAL3MBTL1 | |
| SCHEMBL12966674 | 0.81 | PPARA (0.63) | MAPTNPC1RAB9AL3MBTL1PLA2G4B | |
| SCHEMBL845348 | 0.80 | NPSR1 (0.79) | MAPTNPC1RAB9AKMT2ANPSR1 | |
| SCHEMBL12966650 | 0.80 | MAPT (0.60) | MAPTNPC1RAB9AKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8034797-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN PHARMA GMBH (CH) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | MAPT 1925/4885NPC1 264/4885RAB9A 409/4885 |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | MAPT 1925/4885NPC1 264/4885RAB9A 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.